A Phase 2, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-Term Safety and Tolerability of Tacrolimus in Stable Liver Transplant Patients Converted From a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen.
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2013
At a glance
- Drugs Tacrolimus (Primary)
- Indications Liver transplant rejection
- Focus Pharmacokinetics
- Sponsors Astellas Pharma; Astellas Pharma US
- 08 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Nov 2008 Planned end date changed from 1 Oct 2008 to 1 Dec 2008.
- 24 Oct 2006 New trial record.